Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TriVex, Dyonics Launches To Spur 2003 Endoscopy Sales, S&N Predicts

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew is attributing declining sales of its BoneCutter disposable arthroscopy blade sales in the first half of 2003 to increased reuse of the products following the enactment of the Medical Device User Fee & Modernization Act

You may also be interested in...

ATS bankruptcy

Smith & Nephew will gain full control of the Dermagraft tissue-engineered dermal replacement product joint venture with Advanced Tissue Sciences via a proposed purchase of ATS' stake for $12 mil. ATS, which filed for Chapter 11 protection Oct. 10 in southern California federal bankruptcy court, expects to be advanced up to $5 mil. of the purchase price to continue operations until the sale is approved by the court. In addition to Dermagraft for diabetic foot ulcers, the deal includes TransCyte temporary skin cover for serious burns; combined sales are expected to reach $8 mil. this year, S&N says. Upon completion of the deal, S&N will become a contract manufacturer for non-wound care products retained by ATS. The companies will dissolve their NeoCyte human cartilage development joint venture...

ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts